Jennison Associates
NTLA icon

Jennison Associates’s Intellia Therapeutics NTLA Stock Holding History

Jennison Associates’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-60,000
Closed -$9.71M – 705
2021
Q2 		$9.71M Buy
+60,000
New +$4.67M 0.01% 460

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates's NTLA Position: Q4 2024 in Review

Jennison Associates sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 47,899 shares — an estimated $984K sold.

Jennison Associates first reported a position in NTLA in Q4 2020 and held it in 12 quarters. The position peaked at $173M in Q2 2021. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Jennison Associates reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jennison Associates sold 47,899 Intellia Therapeutics shares in Q4 2024, an estimated $984K.
  • Jennison Associates first reported a position in Intellia Therapeutics in Q4 2020 and held it in 12 quarters.
  • Jennison Associates's Intellia Therapeutics position peaked at $173M in Q2 2021.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Jennison Associates's 13F filing for Q4 2024, filed 24 Jan 2025.